(Axios) – Food and Drug Administration advisers Friday will weigh the risk of premature patient deaths from adverse events when they consider expanding the use of two CAR-T therapies for multiple myeloma. Why it matters: CAR-T treatments have shown promise in the way they can reprogram a patient’s immune cells to attack cancer cells but are pricey and have been flagged before for safety concerns. (Read More)